Cart
sales@molnova.com
ML390
CAS No. 2029049-79-2
ML390 ( —— )
Catalog No. M22425 CAS No. 2029049-79-2
ML390 exerts its potent differentiation effect on multiple leukemia models.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 50 | In Stock |
|
| 10MG | 65 | In Stock |
|
| 25MG | 110 | In Stock |
|
| 50MG | 170 | In Stock |
|
| 100MG | 302 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML390
-
NoteResearch use only, not for human use.
-
Brief DescriptionML390 exerts its potent differentiation effect on multiple leukemia models.
-
DescriptionML390 exerts its potent differentiation effect on multiple leukemia models.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2029049-79-2
-
Formula Weight406.4
-
Molecular FormulaC21H21F3N2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:27 mg/mL (66.44 mM)
-
SMILESFC(F)(F)Oc1ccc(cc1)C(=O)NCCC(=O)N[C@@H]1CCCc2ccccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sykes DB et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. National Center for Biotechnology Information (US); 2010-2013 Dec 15.
molnova catalog
related products
-
Ecliptasaponin A
Ecliptasaponin A has protective effects against the pulmonary fibrosis induced by bleomycin via reducing the oxidative stress, lung tissue inflammation, and the subsequent epithelial-mesenchymal transition.
-
Trioxsalen
Trioxsalen is a furanocoumarin and a psoralen derivative, in conjunction with UV-A for phototherapy treatment of vitiligo and hand eczema.
-
Lenacapavir
Lenacapavir is a potent capsid-targeting inhibitor of HIV replication. Lenacapavir shows anti-HIV activity with an EC50 of 100 pM in MT-4 cells.
